Zoetis
Inc. (NYSE: ZTS) today announced the appointment of Dr. Linda
Rhodes, an accomplished scientist, academic, veterinarian and business
leader in animal health, to its Board of Directors. Her appointment is
effective at the close of business today, and she will serve on the
Quality and Innovation Committee of the Board.
“I am very pleased to welcome Dr. Rhodes to the Zoetis Board of
Directors,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “As an
experienced veterinarian, highly respected researcher and proven
executive in the animal health industry, Dr. Rhodes brings a unique
combination of skills and perspectives to our Board. Her experience and
insights will be valuable as Zoetis navigates the changing landscape and
new technologies we need to ensure our continued growth as the world
leader in animal health.”
Dr. Rhodes has extensive experience as a research scientist, academic,
veterinary practitioner and business leader, spanning nearly 30 years
across the animal health industry. Dr. Rhodes most recently served as
the Chief Scientific Officer of Aratana Therapeutics, a publicly traded
animal health company, from 2012 to 2016, and she had also served as
Chief Executive Officer of Aratana from 2011 to 2012. She is a founder
of AlcheraBio, LLC, a veterinary contract research organization, and
held research and development positions at Merial, Merck & Company, and
Sterling-Winthrop Drug Company. Dr. Rhodes also held several teaching
positions and worked as a bovine veterinarian in private practice for
many years. Dr. Rhodes earned her Ph.D. in Physiology from Cornell
University and her V.M.D. from the University of Pennsylvania. She is
currently an adjunct professor for the Graduate School of Animal Science
at Rutgers University and a member of the Board of Directors of ImmuCell
Corporation, a publicly traded animal health company.
About Zoetis
Zoetis
is the leading animal health company, dedicated to supporting its
customers and their businesses. Building on more than 60 years of
experience in animal health, Zoetis discovers, develops, manufactures
and markets veterinary vaccines and medicines, complemented by
diagnostic products, genetic tests, biodevices and a range of services.
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
more than 100 countries. In 2016, the company generated annual revenue
of $4.9 billion with approximately 9,000 employees. For more
information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements
: This
press release contains forward-looking statements, which reflect the
current views of Zoetis with respect to future events. These statements
are not guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more of
these risks or uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ materially
from those contemplated by a forward-looking statement. Forward-looking
statements speak only as of the date on which they are made. Zoetis
expressly disclaims any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of risks,
uncertainties and other matters can be found in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2016, including in the
sections thereof captioned “Forward-Looking Statements and Factors That
May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly
Reports on Form 10-Q and in our Current Reports on Form 8-K. These
filings and subsequent filings are available online at
www.sec.gov
,
www.zoetis.com
,
or on request from Zoetis.
.
Zoetis
Media:
Bill Price, 973-443-2742
william.price@zoetis.com
or
Elinore White, 973-443-2835
elinore.y.white@zoetis.com
or
Investor:
Steve Frank, 973-822-7141
steve.frank@zoetis.com